Cavan John T. - 18 May 2021 Form 4 Insider Report for Hepion Pharmaceuticals, Inc. (HEPA)

Role
Chief Financial Officer
Signature
/s/ John Cavan
Issuer symbol
HEPA
Transactions as of
18 May 2021
Net transactions value
$0
Form type
4
Filing time
20 May 2021, 16:35:39 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HEPA Stock Options Award $0 +1,200,000 +315% $0.000000 1,581,060 18 May 2021 Common Stock 1,200,000 $1.70 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock Options have been granted subject to stockholder approval of an increase in the shares of common stock issuable pursuant to the 2013 Equity Incentive Plan.
F2 400,000 of the stock options vest on 5/18/2022 and the remainder vests monthly in equal amounts over 24 months.